AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21277062 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam and 1‐μg/kg fentanyl
Number of subjects: 60
Study 21277062 — intervention group
Group type: COMPARATOR
Intervention: midazolam only
Number of subjects: 60
Study 19843062 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (education on disease state, medications, and breathing techniques)
Number of subjects: 173
Study 19843062 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 173
Study 19843062 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control) group
Number of subjects: 173
Study 16488953 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID ophthalmic solution (sodium 2‐amino‐3‐(4‐bromobenzoyl) phenylacetate sesquihydrate) administered for 12 weeks
Number of subjects: 16
Study 16488953 — intervention group
Group type: COMPARATOR
Intervention: Sodium hyaluronic acid ophthalmic solution (control group) administered for 12 weeks
Number of subjects: 16
Study 15602823 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic childhood constipation (CCC)
Number of subjects: 120
Study 11128921 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingivoplasty (GP+) performed 2 months after initial grafting
Number of subjects: 6
Study 11128921 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (GP-)
Number of subjects: 6
Study 11128921 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingivoplasty (GP+)
Number of subjects: 6
Study 9304635 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of oral ketorolac tromethamine (KT) 2 hours prior to surgery
Number of subjects: 63
Study 9304635 — intervention group
Group type: COMPARATOR
Intervention: 0.03% flurbiprofen sodium (FS) topical solution
Number of subjects: 63
Study 9304635 — intervention group
Group type: COMPARATOR
Intervention: Topical normal saline
Number of subjects: 63
Study 8141723 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant hirudin
Number of subjects: 12000
Study 8141723 — intervention group
Group type: COMPARATOR
Intervention: Standard doses of heparin
Number of subjects: 12000
Study 3087694 — intervention group
Group type: EXPERIMENTAL
Intervention: Norplant-2 (two covered rods)
Number of subjects: 172
Study 3087694 — intervention group
Group type: COMPARATOR
Intervention: Norplant (six capsules)
Number of subjects: 172
Study 30626347 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental hemodialysis (1 session per week)
Number of subjects: 152
Study 30626347 — intervention group
Group type: COMPARATOR
Intervention: Thrice-weekly hemodialysis regimen
Number of subjects: 152
Study 27770188 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fat (SFA, butter)
Number of subjects: 20
Study 27770188 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fat (PUFA, grapeseed oil)
Number of subjects: 20
Study 27770188 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic-index (GI) carbohydrate (basmati rice)
Number of subjects: 20
Study 27770188 — intervention group
Group type: EXPERIMENTAL
Intervention: High-glycemic-index (GI) carbohydrate (jasmine rice)
Number of subjects: 20
Study 27770188 — intervention group
Group type: COMPARATOR
Intervention: Monounsaturated fat (MUFA, olive oil)
Number of subjects: 20
Study 27506486 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraciliary microstenting with phacoemulsification
Number of subjects: 505
Study 27506486 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification only (control)
Number of subjects: 505
Study 24490949 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger (1600 mg daily for 12 weeks)
Number of subjects: 70
Study 24490949 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1600 mg wheat flour daily for 12 weeks)
Number of subjects: 70
Study 22539747 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote computer-based logMAR visual acuity measurement
Number of subjects: 0
Study 22539747 — intervention group
Group type: COMPARATOR
Intervention: In-person optometrist presence
Number of subjects: 0
Study 20435345 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (25,000 IU retinol equivalents)
Number of subjects: 207781
Study 20435345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207781
Study 20435345 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 207781
Study 17689142 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise for 12 weeks in addition to usual care (N=8)
Number of subjects: 18
Study 17689142 — intervention group
Group type: COMPARATOR
Intervention: Usual care (N=10)
Number of subjects: 18
Study 16198982 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HT-receptor antagonists (standard dose, IV/oral)
Number of subjects: 691
Study 16198982 — intervention group
Group type: COMPARATOR
Intervention: Prochlorperazine every 8 h
Number of subjects: 691
Study 16198982 — intervention group
Group type: COMPARATOR
Intervention: Prochlorperazine as needed
Number of subjects: 691
Study 11791959 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin
Number of subjects: 76
Study 11791959 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 76
Study 9589243 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone 400 mg daily for 8 weeks
Number of subjects: 15
Study 9589243 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 15
Study 7998769 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange (twice a week for 3 weeks then once a week for 3 weeks)
Number of subjects: 20
Study 7998769 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune globulin infusion (0.4 gm/kg once a week for 3 weeks, then 0.2 gm/kg once a week for the next 3 weeks)
Number of subjects: 20
Study 7998769 — intervention group
Group type: COMPARATOR
Intervention: Plasma exchange
Number of subjects: 20
Study 7998769 — intervention group
Group type: COMPARATOR
Intervention: Immune globulin infusion
Number of subjects: 20
Study 2897788 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamic acid 500 mg orally three times daily plus vincristine 1.0 mg/m2 weekly for six doses
Number of subjects: 84
Study 2897788 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus vincristine 1.0 mg/m2 weekly for six doses
Number of subjects: 84
Study 30726984 — intervention group
Group type: EXPERIMENTAL
Intervention: Tar condition
Number of subjects: 531
Study 30726984 — intervention group
Group type: COMPARATOR
Intervention: No-tar condition
Number of subjects: 531
Study 29017421 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive medication reviews (CMRs) by intervention pharmacists
Number of subjects: 37
Study 26927249 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose add-back therapy (estradiol valerate 1 mg and medroxyprogesterone acetate 2.5 mg, once a day)
Number of subjects: 107
Study 26927249 — intervention group
Group type: COMPARATOR
Intervention: Regular-dose add-back therapy (estradiol valerate 1 mg and medroxyprogesterone acetate 2.5 mg, twice a day)
Number of subjects: 107
Study 26927249 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (low dose and regular dose)
Number of subjects: 107
Study 24690416 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg Atomoxetine (ATX)
Number of subjects: 0
Study 24690416 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Hz rTMS
Number of subjects: 0
Study 24690416 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 10 Hz rTMS and 60 mg ATX
Number of subjects: 0
Study 24690416 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 22332914 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes scorecard
Number of subjects: 103
Study 22332914 — intervention group
Group type: COMPARATOR
Intervention: Control group (no diabetes scorecard)
Number of subjects: 103
Study 20836938 — intervention group
Group type: EXPERIMENTAL
Intervention: EMR-based prompts and education
Number of subjects: 67000
Study 20836938 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67000
Study 18607811 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional Work Grant (TWG) program
Number of subjects: 0
Study 18607811 — intervention group
Group type: COMPARATOR
Intervention: Nonparticipating companies (NTW)
Number of subjects: 0
Study 16211736 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg and paracetamol 1.5 g
Number of subjects: 40
Study 16211736 — intervention group
Group type: COMPARATOR
Intervention: Placebo and paracetamol 1.5 g
Number of subjects: 40
Study 11919671 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 14
Study 11919671 — intervention group
Group type: COMPARATOR
Intervention: Amino acid cocktail drink without tryptophan (control)
Number of subjects: 14
Study 10978986 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (0.5 mg)
Number of subjects: 52
Study 10978986 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 52
Study 8658044 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy (21/min by nasal prongs)
Number of subjects: 89
Study 8658044 — intervention group
Group type: COMPARATOR
Intervention: Control group (no oxygen therapy)
Number of subjects: 89
Study 8658044 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Number of subjects: 89
Study 1610863 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-drug therapy (cyclosporine, azathioprine, and prednisolone)
Number of subjects: 112
Study 1610863 — intervention group
Group type: COMPARATOR
Intervention: Double-drug therapy (cyclosporine and azathioprine)
Number of subjects: 112
Study 1610863 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-drug therapy
Number of subjects: 112
Study 1610863 — intervention group
Group type: COMPARATOR
Intervention: Double-drug therapy
Number of subjects: 112
Study 6734370 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 90 mg QID
Number of subjects: 15
Study 6734370 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem (90, 120, 150 mg)
Number of subjects: 15
Study 30962245 — intervention group
Group type: EXPERIMENTAL
Intervention: StopApp (intervention) - a brief online behaviour change intervention designed to address barriers to SSS attendance.
Number of subjects: 162
Study 30962245 — intervention group
Group type: COMPARATOR
Intervention: Standard promotion of and referral to SSSs (control) - standard web-based information about the SSSs.
Number of subjects: 162
Study 29684295 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban residents
Number of subjects: 400
Study 29684295 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural residents
Number of subjects: 400
Study 29684295 — intervention group
Group type: COMPARATOR
Intervention: Overall smoking prevalence
Number of subjects: 400
Study 27107959 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel patient information resource (website and booklet)
Number of subjects: 70
Study 27107959 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 70
Study 24626733 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with 14 mL of 0.75% ropivacaine plus 4.0 mcg/kg of clonidine
Number of subjects: 80
Study 24626733 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia with 14 mL of ropivacaine 0.75 % plus 0.0266 mL/kg of 0.9% saline solution
Number of subjects: 80
Study 23092451 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly supplementation of 2800 μg folic acid
Number of subjects: 5011
Study 23092451 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly supplementation of 60 mg iron and 2800 μg folic acid
Number of subjects: 5011
Study 23092451 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly supplementation of multiple micronutrients (MM)
Number of subjects: 5011
Study 23092451 — intervention group
Group type: COMPARATOR
Intervention: Current practice of prenatal IFA supplementation only
Number of subjects: 5011
Study 21053992 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 0.5 mg intravenously
Number of subjects: 36
Study 21053992 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 2.5 mg intravenously
Number of subjects: 36
Study 21053992 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg intravenously and 10 mg oral tablet (crossover)
Number of subjects: 36
Study 21053992 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 10 mg intravenously
Number of subjects: 36
Study 21053992 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 36
Study 17622876 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixion nail (DiscOTech, Monroe Township, NJ)
Number of subjects: 20
Study 17622876 — intervention group
Group type: COMPARATOR
Intervention: Zimmer M/DN locked nail (Zimmer, Warsaw, IN)
Number of subjects: 20
Study 15723872 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of covariance (ANCOVA)
Number of subjects: 0
Study 15723872 — intervention group
Group type: COMPARATOR
Intervention: Change score or percentage change score
Number of subjects: 0
Study 11390726 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron sucrose (250 mg iron diluted in 100 ml normal saline given over 60 min once per month)
Number of subjects: 55
Study 11390726 — intervention group
Group type: COMPARATOR
Intervention: Iron gluconate (62.5 mg iron given once per week in a slow push injection)
Number of subjects: 55
Study 9422429 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic oral ganciclovir (1000 mg p.o. t.i.d.; n=19)
Number of subjects: 42
Study 9422429 — intervention group
Group type: COMPARATOR
Intervention: Deferred therapy (Acyclovir 200 mg p.o. b.i.d.; n=23)
Number of subjects: 42
Study 8388275 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhesus-human reassortant tetravalent rotavirus vaccine (4 x 10^4 plaque forming units)
Number of subjects: 194
Study 8388275 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhesus-human reassortant tetravalent rotavirus vaccine
Number of subjects: 194
Study 8388275 — intervention group
Group type: COMPARATOR
Intervention: Non-breast-fed infants (comparison group)
Number of subjects: 194
Study 2834480 — intervention group
Group type: EXPERIMENTAL
Intervention: PK 10169 at 0.75 mg/kg
Number of subjects: 42
Study 2834480 — intervention group
Group type: EXPERIMENTAL
Intervention: PK 10169 at 1 mg/kg
Number of subjects: 42
Study 2834480 — intervention group
Group type: EXPERIMENTAL
Intervention: PK 10169 at 1.25 mg/kg
Number of subjects: 42
Study 2520420 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 30
Study 2520420 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 30
Study 30770931 — intervention group
Group type: EXPERIMENTAL
Intervention: WASH intervention (ventilated improved pit latrine, two hand-washing stations, liquid soap, chlorine, infant play space, hygiene counseling)
Number of subjects: 801
Study 30770931 — intervention group
Group type: EXPERIMENTAL
Intervention: WASH intervention
Number of subjects: 801
Study 28818316 — intervention group
Group type: EXPERIMENTAL
Intervention: CPACS Risk Score (RS)
Number of subjects: 6790
Study 28818316 — intervention group
Group type: COMPARATOR
Intervention: GRACE Risk Score (RS)
Number of subjects: 6790
Study 26026494 — intervention group
Group type: EXPERIMENTAL
Intervention: CM+TAU
Number of subjects: 176
Study 26026494 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 176
Study 23614849 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-managed intervention
Number of subjects: 374
Study 23614849 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic added during first month
Number of subjects: 374
Study 23614849 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 374
Study 21406599 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.2%
Number of subjects: 10
Study 21406599 — intervention group
Group type: EXPERIMENTAL
Intervention: Apraclonidine 0.5%
Number of subjects: 10
Study 21406599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 19095506 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine-clonidine infusion before anesthesia induction
Number of subjects: 50
Study 19095506 — intervention group
Group type: COMPARATOR
Intervention: Standard anesthesia
Number of subjects: 50
Study 16549465 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (25.8% of energy intake from fat)
Number of subjects: 61
Study 16549465 — intervention group
Group type: EXPERIMENTAL
Intervention: High monounsaturated fatty acid (MUFA) diet (40.1% of energy intake from fat, 22.5% from MUFA)
Number of subjects: 61
Study 16549465 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 61
Study 14695735 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 2703
Study 14695735 — intervention group
Group type: COMPARATOR
Intervention: Intravenous meperidine analgesia
Number of subjects: 2703
Study 11767175 — intervention group
Group type: EXPERIMENTAL
Intervention: Silzone-coated valves
Number of subjects: 95
Study 11767175 — intervention group
Group type: COMPARATOR
Intervention: Uncoated valves
Number of subjects: 95
Study 9268955 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium nicotinate supplementation with exercise training
Number of subjects: 0
Study 9268955 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium picolinate supplementation
Number of subjects: 0
Study 9268955 — intervention group
Group type: COMPARATOR
Intervention: Exercise training alone
Number of subjects: 0
Study 8261775 — intervention group
Group type: EXPERIMENTAL
Intervention: MULCOX2 program for Cox regression analysis
Number of subjects: 0
Study 3543049 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (180 or 240 mg/day)
Number of subjects: 0
Study 3543049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31146305 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Training Group (FTG)
Number of subjects: 39
Study 28648913 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (10 mg extended release b.i.d)
Number of subjects: 20
Study 28648913 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (37.5 mg extended release b.i.d)
Number of subjects: 20
Study 28648913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 26556692 — intervention group
Group type: EXPERIMENTAL
Intervention: One year of free school fruit (daily one piece of fruit or vegetable)
Number of subjects: 320
Study 23238152 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine
Number of subjects: 105607
Study 21531512 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine surgical intervention for closure of the vertebral defect
Number of subjects: 0
Study 19894656 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure measurements from the first visit (HTN1)
Number of subjects: 739
Study 19894656 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure measurements from the second visit (HTN2)
Number of subjects: 739
Study 19894656 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure measurements from both visits (HTN(Final))
Number of subjects: 739
Study 19894656 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness based on first visit
Number of subjects: 739
Study 19894656 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment based on first visit
Number of subjects: 739
Study 19894656 — intervention group
Group type: EXPERIMENTAL
Intervention: Control based on first visit
Number of subjects: 739
Study 19894656 — intervention group
Group type: EXPERIMENTAL
Intervention: HTN(Final) with body mass index > or = 30
Number of subjects: 739
Study 19894656 — intervention group
Group type: EXPERIMENTAL
Intervention: HTN(Final) with left ventricular hypertrophy
Number of subjects: 739
Study 16434649 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality visual-feedback cues
Number of subjects: 16
Study 16434649 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 16
Study 14628989 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 40 mg/day
Number of subjects: 348
Study 14628989 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 60 mg/day
Number of subjects: 348
Study 14628989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 348
Study 14628989 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (any dose)
Number of subjects: 348
Study 14628989 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 348
Study 11405344 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human alpha‐Gal A (r‐halphaGal A) replacement therapy for Fabry disease
Number of subjects: 0
Study 9404906 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime (10 mg/kg to 12 mg/kg per day in two divided doses)
Number of subjects: 85
Study 9404906 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol (100 mg/kg daily in four divided doses)
Number of subjects: 85
Study 8388231 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus verapamil (480 mg day‐1 for 3 days prior to chemotherapy)
Number of subjects: 72
Study 8388231 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 72
Study 3317054 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg/kg every six hours for 24 hours)
Number of subjects: 99
Study 3317054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 30694963 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat Gripz (FG)
Number of subjects: 15
Study 31364266 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 0
Study 31364266 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 0
Study 28838583 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Aripiprazole 10 to 30 mg/d
Number of subjects: 201
Study 28838583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 26614965 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP with oral emtricitabine and tenofovir disoproxil fumarate
Number of subjects: 339
Study 26614965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 339
Study 23335369 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP treatment with MYC, BCL2, and BCL6 rearrangements and protein expression analysis
Number of subjects: 442